Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2026 | CITADEL: neoadjuvant sacituzumab govitecan and pembrolizumab in NSCLC

Molly Li, MBBS, MRCP, FHKCP, FHKAM , The Chinese University of Hong Kong, Hong Kong, China, discusses the Phase II CITADEL (NCT06055465) study of neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by surgery and adjuvant pembrolizumab, in patients with resectable stage II–III, EGFR/ALK wild-type non-small cell lung cancer (NSCLC). Among resected patients, pathologic complete response rates were low and did not improve on those seen with standard perioperative chemo-immunotherapy. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Essentially Citadel is a study that investigates perioperative immune checkpoint inhibitor plus an antibody drug conjugate in patients with resectable lung cancer. So we know that perioperative immunochemotherapy is now the center of care for patients with resectable lung cancer but still recurrence rate remains high and there is room to improve the pathological complete response rate...

Essentially Citadel is a study that investigates perioperative immune checkpoint inhibitor plus an antibody drug conjugate in patients with resectable lung cancer. So we know that perioperative immunochemotherapy is now the center of care for patients with resectable lung cancer but still recurrence rate remains high and there is room to improve the pathological complete response rate. So based on this, based on the knowledge that we have with previous data showing promising objective response rate using pembrolizumab and sacituzumab govitecan, a TROP2 antibody drug conjugate in the late-stage setting, we tried to investigate the efficacy of this combination in early-stage setting. So in short, this is a multi-center investigator-initiated phase two trial that was conducted in Hong Kong, five centers, that enrolled patients with stage two to three potentially resectable non-small cell lung cancer without EGFR or ALK alteration. Enrolled participants will receive four cycles of pembrolizumab and also day 1, day 8, sacituzumab govitecan, followed by surgical resection and then another 13 cycles of adjuvant pembrolizumab. The primary endpoint is the pathological complete response rate in the intention to treat population, and secondary endpoints include pathological complete response rate in the patients who received resection, major pathological response rates, safety, 12-month and 24-month event-free survival. And in ESMO this year, we are presenting the results of the primary endpoint, the PCR in the ITT population, as well as some secondary endpoints, including safety and major pathological responses. So in this study, we enrolled 37 participants, among which 36 were analyzed, and all of them received neoadjuvant treatment. Subsequently, among these participants, most of them were stage 3, 80% of them stage 3, and the majority of them, two-thirds of them, being smokers, as well as adenocarcinoma in histology. So after all of them received four cycles of treatment and then among which 30 of them received surgery. So around 80% of them had surgery which is in line with what we know about perioperative immunochemotherapy in literature. Regarding the primary endpoint, the pathological complete response is however a bit disappointing. It is actually only four out of 36 achieved pathological complete response which is 11 percent that did not meet our statistical objective and so this is a negative study. Regarding the major pathological response, we had a response rate of 33% among the 36 population. Regarding the safety, generally it’s quite well tolerated. Most common side effects include rash in 50% of cases, and then other side effects include nausea, vomiting, diarrhea, as well as neutropenia, which is mostly in line with what we know about the antibody drug conjugates as a TROP2 ADC. So in summary, the importance of this trial is that although it’s negative, it’s one of the first reported trials that evaluated an anti-PD-1 plus TROP2-ADC combination in resectable non-small cell lung cancer. Although it’s negative, I’m sure this will provide us some insights in how to design future perioperative systemic therapy studies, as well as the translational studies that will follow on the potential changes in tumor microenvironment and resistance mechanism with the TROP2 ADC that will provide us extra insights. So this is a negative study, but overall there are no additional safety findings. So hopefully I have given a nice summary of this phase two trial.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.